长按二维码,关注官方公众号
使用微信扫一扫分享到朋友圈
使用微信扫一扫进入小程序分享活动
Andrea Cossarizza (born December 11th, 1958) took the degree in Medicine and Surgery at the University of Padua, then he did his PhD in Oncology at the University of Bologna and University of Modena, and the Specialization in Clinical Pathology and Immunohematology at the University of Modena and Reggio Emilia. When he was a medical student, he visited the Basel Institute of Immunology and then the New York University (NYU) Medical Center. After the degree, he spent some periods in different Institutes (Charing Cross Sunley Res. Ctr., London; Univ. Cochin, Paris; University of Califormia at Los Angeles - UCLA), in 1998 he became Associate Professor of General Pathology and Immunology at the University of Modena and Reggio Emilia, and in 2010 was appointed Full Professor (office taken in 2013).
Professor Adrian V. S. Hill FRS is the Director and Founder of the Jenner Institute, and Mital Professor of Vaccinology at Oxford University. He is a passionate believer in the power of molecular medicine to address many of the most egregious health care inequities globally. His group have been leaders in the development of adenoviral and other vaccines against infectious diseases and he has tested these in extensively in over eighty clinical trials in Africa and Europe. In partnership with the Serum Institute of India and AstraZeneca the Jenner Institute developed rapidly a ChAdOx1 vector-based SARS-CoV-2 vaccine which saved an estimated 6.2 million lives in 2021 alone.
His lab also designed a newly licensed high efficacy malaria vaccine, R21/Matrix-MTM, which has recently shown unprecedented high efficacy in a phase III trial in four African countries, again in partnership with the Serum Institute of India and also Novavax Inc. This vaccine promises to make a major impact on reducing the 500,000 childhood deaths from malaria each year. In 2021 he was elected a Fellow of the Royal Society and is a Knight Commander of the Order of the British Empire (KBE).
Amine Kamen is Professor of Bioengineering at McGill University, and Canada Research Chair in Bioprocessing of Viral Vaccines. He is Researcher Emeritus of the National Research Council of Canada (NRC) where he was employed until early 2014, as head of the Process Development section of the Human Health Therapeutics Portfolio. At NRC, he established one of the North America largest and most advanced governmental centers for animal cell culture addressing process development and scale up of biologics. Also, he developed with his team and licensed to industry multiple technology platforms for efficient manufacturing of recombinant proteins and viral vectors and vaccines and led technology transfer to manufacturing sites for clinical evaluation and commercialization. His current research activities focus on uncovering mechanisms associated with cell production of viral vectors and viral vaccines; cell and metabolic engineering; process control and monitoring; and process analytical technologies and digitalization of intensified productions of viral vectors for gene delivery and vaccination. He published close to two hundred papers in refereed international journals and acts as experts on scientific advisory committees for several national and international private and public organizations in the Biomanufacturing and Life Sciences sector.
Bali Pulendran, PhD
Violetta L. Horton Professor, and Director of the Institute for Immunity, Transplantation and Infection,
Department of Pathology, Department of Microbiology and Immunology, Fellow at ChEM-H (Chemistry,
Engineering and Medicine for Human Health), Stanford University School of Medicine, Stanford University.
Bali Pulendran is the Violetta L. Horton Professor at the Stanford University School of Medicine, and
Director of the Institute for Immunology, Transplantation, and Infection, at Stanford University. He
received his undergraduate degree from Cambridge University, and his Ph.D., from the Walter & Eliza Hall
Institute in Melbourne, Australia, under the supervision of Sir Gustav Nossal. He then did his postdoctoral
work at Immunex Corporation in Seattle.
Dr. Pulendran has had a transformative impact on human immunology and vaccinology by pioneering the
use of systems approaches to probe immunity to vaccination and infection in humans. In addition, Dr.
Pulendran discovered that dendritic cells, one of the key cell types orchestrating the immune response,
consist of multiple subtypes, which are functionally distinct. He also discovered the mechanisms by which
microbial stimuli program DCs to modulate T-helper responses and helped establish Flt3-Ligand as the
key growth factor for DCs in vivo. These groundbreaking findings helped define major paradigms in innate
immunity.
Dr. Pulendran’s research is published in front line journals such as Nature, Science, Cell, Nature Medicine,
and Nature Immunology. Dr. Pulendran serves on many advisory boards including that of Keystone
Symposia and on the External Immunology Network of GSK. He is a fellow of the American Association for
the Advancement of Science and the recipient of several honors and awards, including two concurrent
MERIT awards from the NIH, the AAI Ralph Steinman Award for Human Immunology, the Albert Levy
Prize, the ViE Award for the Best Research Team at the World Vaccine Congress, and is listed
on Thomson Reuter’s list of Highly Cited Researchers, which recognizes the world's most influential
researchers of the past decade, demonstrated by the production of multiple highly-cited papers that rank
in the top 1% by citations.
Professor Cheol-Heui YUN grew up in Gwang-ju, a southwest region of Republic of Korea. He was educated at the Chonnam National University for B. Sc. and the Seoul National University for his M. Sc. in Animal Nutrition. He obtained his Ph. D. at the University of Saskatchewan, Canada in the area of immune modulation and mucosal immunology. Then, he pursued his professional career at leading research institutes in different region of the world including International Vaccine Institute (IVI, Korea), USDA and NIH (MD, USA) and Gothenburg University (Sweden) where he undertook research related to stress, vaccine/adjuvant, infection and host protective immunity.
He published over 290 SCIE papers to date and has been the recipient of prestigious awards, including Cargill-KAST (Korean Academy of Science and Technology) Bioscience Award (2023), Seoul National University Excellence in Teaching Award (2018), Distinguished teaching award by Kukdam Foundation (2010), and official commendation for from the cabinet minister of the Ministry of Science and Technology (2007, 2022). For scientific researches, Prof. Yun and his team have focused on the action mechanism of protective immune responses against various biological stresses including infection, mucosal immunity, vaccine/adjuvant, systems serology and nutritional immunology and immunometabolism. Currently, he is a member of the Korean Academy of Science and Technology (KAST) since 2023.
My research, funded by UK Medical Research Council fellowships (Career Development Award: 2019 – 2024; and Senior Fellowship: 2024 - 2029) and US National Institute of Health grants, focuses on next-generation vaccines against major bacterial pathogens. Using the chief causes of bacterial meningitis as exemplar, my lab is currently employing innovative use of Reverse Vaccinology 2.0, and bacterial and synthetic cell glycoengineering to the development of a next-generation, combined meningococcal-pneumococcal glycoconjugate vaccine. Efforts in my lab are also geared towards understanding the human adaptive immunity to, and prevention of disease due to, AMR pathogens of concern, Neisseria gonorrhoeae and Klebsiella pneumoniae.
Dr. Siber is an infectious disease trained physician with more than 40 years of experience in developing vaccines and antibody products. From 1996 to 2007, Dr. Siber served as Executive Vice President and Chief Scientific Officer of Wyeth Vaccines (now Pfizer) where he led the development and approval of multiple innovative childhood vaccines, including Prevenar 7 and 13, the first pneumococcal conjugate vaccines, Rotashield, the first rotavirus diarrhea vaccine, Meningitec, the first meningococcal meningitis conjugate vaccine and FluMist, the first nasal influenza vaccine. Prior to Wyeth, Dr. Siber was Harvard Medical School Associate Professor of Medicine at Dana Farber Cancer Institute and Director of the Massachusetts Public Health Biologic Laboratories where he developed multiple vaccines and immune globulins, including Respigam, the first antibody licensed for respiratory syncytial virus. Dr. Siber most recently was a Co-founder and Board Member of Affinivax which developed a 24 valent pneumococcal vaccine and was acquired by GSK in 2022. Dr. Siber currently serves on the Scientific Advisory Boards of AdVaccine, CanSino, Clover, Everest Medicines, ILiAD, Valneva, Vaxart and Vaxxinity and has been a consultant to the NIH, EU, WHO and the Gates Foundation. Dr.Siber was member of the Board of Trustees of the International Vaccine Institute. Dr Siber has received multiple awards including the 2016 Albert Sabin Gold Medal in vaccinology. Dr. Siber holds an MD degree from McGill University in Canada, received post‑doctoral training in Internal Medicine at Rush‑Presbyterian Hospital in Chicago and Beth Israel Hospital in Boston and training in Infectious Diseases and Vaccinology at Boston Children’s Hospital and Beth Israel Hospital, Harvard Medical School.
Dr. Haitao Hu is a Professor at the Institute of Microbiology, Chinese Academy of Sciences. Prior to joining the Institute, Dr. Hu was a tenured associate professor at the University of Texas Medical Branch (UTMB) Department of Microbiology and Immunology, where he was also a faculty member of the Sealy Institute for Vaccine Sciences and served on its Executive Committee. He received his PhD in Microbiology and Virology from the University of Pennsylvania under the mentorship of Nobel Laureate Dr. Drew Weissman.
Dr. Hu’s research focuses on viral immunology and development of mRNA-based broad-spectrum vaccines for RNA viruses, including HIV and respiratory pathogens. Through collaboration with other investigators, his laboratory has developed protective mRNA-LNP vaccines against SARS-CoV-2 and avian influenza (H5N1), and continues to advance mRNA vaccine strategies for HIV/AIDS. His laboratory is also developing RNA-delivered monoclonal antibodies as both prophylactics and therapeutics for viral infections. Dr. Hu has served as an expert reviewer for major vaccine-related grant panels (U19 and P01) and as a peer reviewer for leading scientific journals, including Science Translational Medicine, Science Immunology, and Nature Communications.
Dr. Heba Wali is a senior leader in biological products and vaccine manufacturing with over 30 years of experience strengthening public health systems across Africa. She currently serves as Vice CEO of the Vaccines and Biotechnology City (VBC), leading the development of an integrated national ecosystem that connects research, development, and production to ensure manufacturing capacity, equity, and long-term system reliability for human and veterinary vaccines under a One Health approach. Previously, she was General Manager of Biogeneric Pharma Company, achieving GMP and ISO certifications, implementing eQMS and LIMS, and building international partnerships with the Serum Institute of India and Sanofi Pasteur. She also served as CEO of the Holding Company for Biological Products and Vaccines and Chairman and CEO of VACSERA, where she secured sustainable local supply, advanced technology transfer, and strengthened pandemic preparedness during COVID-19 through local production for covid vaccine . Dr. Wali has contributed as a WHO consultant for quality systems and was appointed as project manager for Egyptian National Regulatory Authority, supporting WHO recognition. She holds a PhD, MBA, Diploma in Total Quality Management, is a Certified Project Manager, and a DBA candidate.
Dr. Hun Kim is the President of Global Business at SK Bioscience. His role is to oversee the company's product and platform portfolio in a comprehensive perspective from R&D to commercialization through global alliance and external innovation.
Dr. Hun Kim started his biopharmaceutical career in 1992 as a researcher at Green Cross Corporation, In 2000, he moved on to Berna Biotech, a part of Crucell at present. In 2008, he joined SK Chemicals,the parent company of SK Bioscience, and lead the company's expansion in vaccine R&D, Quality and manufacturing capabilities.
Under his oversight, the company developed and received approval for cell culture-based influenza vaccines (SKYCellflu/SKYCellflu Quadrivalent), varicella/herpes zoster vaccines (SKYVaricella/SKYZoster),and Pneumococcal Conjugation Vaccines. During the Pandemic, it successfully manufactured and supplied COVID-19 vaccines developed by AstraZeneca and NovaVax. With support from CEPI and BMGF, SK Bioscience also developed its own COVID-19 vaccine (SKYCovione), which became the first domestically developed COVID-19 vaccine to be approved in Korea.
Dr. Jing Bao, MD, PhD, is a physician-scientist and global leader in drug development and clinical trials with over 30 years of experience spanning the NIH, the biotech industry, and venture capital. A former NIH clinical trial leader and Chief Medical Officer, she currently serves as a Visiting Professor at the Hong Kong University of Science and Technology, Venture Partner at Shanghai HealthCare Capital, CEO of Apollo Biotechnologies USA, and a member of the Society of Physician Entrepreneurs. She frequently lectures in EMBA and MBA programs on venture capital, life sciences innovation, and global health leadership. Dr. Bao has led global clinical trials, overseen innovative drug pipelines, and driven investments in transformative life-science technologies worldwide, bringing a unique cross-sector perspective to advancing immunotherapies and precision medicine.
John Tsang is a systems immunologist, computational biologist, and engineer. He is the Anthony N. Brady Professor of Immunobiology and Biomedical Engineering at Yale University, the Founding Director of the Yale Center for Systems and Engineering Immunology (CSEI), the Yale Lead and an Investigator at the Chan Zuckerberg Biohub New York, and the co-Chief Scientific Officer of the Human Immunome Project (a non-profit dedicated to mapping human immune variation around the globe to develop AI models of human immune health for the benefit of all). Tsang has pioneered and established the concepts and predictive metrics of human immune setpoints and immune health including responses to vaccines, infections, autoimmunity, and therapeutics in human populations spanning the lifespan from infancy to old age. Tsang is also interested in programming immune cells to facilitate longitudinal immune and health monitoring of the entire body. Tsang has received numerous awards for his research and leadership in systems immunology, COVID-19, and human immunology. He has advised numerous programs and organizations, including the Allen Institute, the Gates Foundation, CEPI, World Allergy Organization, National Cancer Institute, National Institute of Allergy and Infectious Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Snow Medical (Australia), and the Walter and Eliza Hall Institute (Australia). Tsang earned his Ph.D. in biophysics from Harvard University and trained in computer engineering (BASc) and computer science (MMath) at the University of Waterloo, Canada.
Dr. Joon Haeng Rhee is a graduate of Chonnam National University Medical School and received PhD from the same university. He has been working on molecular microbial pathogenesis and vaccine biology for more than 30 years. His team was the first reporter of the whole genome sequence of V. vulnificus, which became one of the most widely used standard strains in the Vibrio research field. Vaccine study was first started aiming the high mortality V. vulnificus infections. During the vaccine research, his team came across the finding that a flagellin protein of V. vulnificus has an excellent mucosal adjuvant activity in late 1990s. Now flagellin is applied to the development of effective vaccines and immunotherapeutics against diverse diseases such as cancers, allergies, and Alzheimer’s disease. He served the president of Korean Vaccine Society (KVS) from 2013 to 2015. He was elected as an ISV Fellow and serves a member of ISV Executive Board. He is currently the director of Clinical Vaccine R&D Center and Combinatorial Tumor Immunotherapy Research Center of Chonnam National University. As of November 2023, he has more than 170 papers published in peer-reviewed journals and named as an inventor on 40 patents.
Professor Kaissar Tabynov, PhD, is a leading vaccine scientist with over 20 years of experience in the development and implementation of vaccines for both human and veterinary use. He has led the creation of three influenza vaccines for healthcare -Refluvac (H1N1), Kazfluvac (H5N1), and Kazfluvir (seasonal flu) - and seven veterinary vaccines, including against avian influenza (H5, H7), equine influenza, and brucellosis. Refluvac and Kazfluvac were the first registered vaccines in Kazakhstan's modern history. Kazfluvir completed Phase I–III clinical trials involving 2,344 volunteers and was deemed safe and immunogenic.
During the COVID-19 pandemic, he led the development of two innovative platforms: NARUVAX-C19, an intramuscular nanoemulsion-based subunit vaccine, and NARUVAX-C19/Nano, an intranasal chitosan nanoparticle vaccine. Both demonstrated high immunogenicity and passed rigorous preclinical safety testing.
Professor Tabynov also spearheads the development of PollenVax, a recombinant allergy vaccine targeting Artemisia pollen-induced rhinitis and asthma. This novel approach offers a promising alternative to traditional allergen-specific immunotherapy (ASIT), with enhanced efficacy and convenience. His work has laid a strong foundation for Kazakhstan’s vaccine technology landscape.
Prof. Ken J. Ishii, M.D., Ph.D., currently Director for Int. Vaccine Design Center, The Institute of Medical Science, the University of Tokyo, has 27 years of experience in Vaccine R&D since 1998 including 7 years as a IND reviewer at US Food and Drug Administration (FDA), 15 years as a basic immunologist at Osaka University, 9 years as a vaccine adjuvant expert at National Institute (NIBIOHN), 2 years as managing director at AMED (medical funding agency), as well as Advisor for PMDA (regulatory agency), GHIT (global fund) and CEPI. He has contributed to basic research on infectious diseases and immunology, resulted in numerous books and over 250 periodical publications and 35,000 citations with H-index 84 as well as over 50 patents related to vaccine and adjuvant, and to regulation of many vaccines and guidelines for vaccine preclinical and clinical trials in Japan and US.
Li Hao, PhD Senior Director NGS & Data Sciences Vaccine R&D Pfizer, Inc Senior Director of Computational Biology and NGS lab with deep R&D experience in pharmaceutical industry on systems biology, bioinformatics, software engineering, genetics, genomics, high-throughput sequencing and vaccine development. She is specialized in applying innovative digital solution (including AI/ML) in mining through ultra-high dimensional and big data to extract biologically meaningful knowledge. She has demonstrated ability to lead and coordinate multi-disciplinary teams to deliver solutions to complex computational biology problems in a matrix organization. Contributed as a core member and bioinformatics lead to the successful licensure of Trumenba vaccine for serogroup B N. meningitidis and Paxlovid for SARS-CoV-2, as well as their post-authorization regulatory support. Currently lead Next-generation Sequencing and Data Sciences team supporting all vaccine programs (including both bacterial and viral programs, e.g. Prevnar NextGen for S. pneumoniae, Covid/Flu combo) and antiviral program from Discovery Sciences. Li received her PhD in Evolutionary Genetics from the Pennsylvania State University, and a Bachelor of Science degree in Genetics and Genetic Engineering from Fudan University. She trained at the post-doctoral level at the McKusick-Nathans Institute of Genetic Medicine at Johns Hopkins University and Langone Medical Center of New York University with Drs. Aravinda Chakravarti and Harry Ostrer. Her postdoctoral studies involved application of a variety of Omics approaches to understand genetic basis of common and rare disorders. Li joined Pfizer Vaccine R&D in 2012.
Dr. Chen has been a Professor at the State Key Lab of Respiratory Disease, Guangzhou Medical University since 2013. Dr. Chen received a medical degree from Shanghai Medical College in 1984. He obtained a Ph.D. in Biochemistry and Molecular Biology from Indiana University School of Medicine. Dr. Chen completed his postdoctoral training at Dana-Farber Cancer Institute, Harvard Medical School. From 1997-2001, Dr. Chen served as a Senior Research Fellow at Merck Research Laboratories, where he was the first inventor of Merck's Ad5-based AIDS vaccine that entered clinical trials worldwide. Dr. Chen served as Vice President of R&D for GlaxoSmithKline in 2009-2011 and as Vice President at Sanofi Pasteur in 2012. Dr. Chen has over 200 publications in infectious diseases, vaccine research, and cancer research. His current research is focused on vaccine and antibody research on adenovirus, influenza virus, and emerging viruses. Since 2020, Dr. Chen has been working on developing user-friendly intranasal vaccines and mucosal immunity.
Luciana C.C. Leite, is Senior Researcher at the Vaccine Development Laboratory, Butantan Institute. She works in Vaccine Development, mainly using recombinant BCG technology and has participated in several of the Brazilian genomic projects with over 150 papers published and several patents. The first product developed, a recombinant BCG strain for improved bladder cancer treatment has the Phase I clinical trial planned for early 2026. She is currently moving forward with the development of a new recombinant BCG strain as an improved vaccine against tuberculosis for both humans and bovines. She has been director of the Biotechnology Center and of the Vaccine Development Laboratory, vice president of the Butantan Foundation, and member of the Steering Committee of the Vaccine Manufacturing Network in Developing Countries (DCVMN) and of the National Technical Commission on Biosafety (CTNBio). She is currently member of the Academic Management Board of the Erasmus Mundus's Leading International Vaccinology Education (LIVE) and of the Brazilian TB Network and has been recently nominated member of Scientific Advisory Committee of the Coalition for Pandemic Preparedness and Innovation (CEPI).
Dr. Maggie Wang is the founder and director of Beth Bioinformatics, a company based in Hong Kong. She is also an Associate Professor in the Faculty of Medicine, the Chinese University of Hong Kong (CUHK). Her research focuses on unveiling mutation patterns in viral and human genome through the development of cutting-edge biotechnology methods. Her major contribution including developing the first-of-the-kind approach to predict vaccine effectiveness through genome analysis (Nature Medicine 2022) that is adopted by national FDA to approve new vaccine product, accurate forecasting of influenza virus evolution (Nature Communications 2024), and prediction for human phenotypes in multiple-population data (PLoS Genetics 2022), among others. She serves as the Editor-in-Chief of Human Genetics (Springer Nature), and is a recipient of Excellent Young Scientists Fund awarded by the National Natural Science Foundation of China. At BethBio, she leads a passionate team to translate their world-leading biotechnologies to facilitate vaccine antigen design and therapeutics developments at international pharmaceutical industry partners.
Marco Cavaleri is Head of Office, Biological Health Threats and vaccines strategy. He is the Chair of EMA COVID Task force and responsible for EMA activities for emergent pathogens, vaccines and AMR.
Marco Cavaleri is a Pharmacologist who spent several years in industry in R&D mainly in the area of anti-infectives covering different positions in preclinical and clinical development.
In 2005 he joined the EMEA as Scientific Administrator in the Scientific Advice and Orphan Drugs Sector, specifically being in charge of anti-infectives and vaccines scientific advice procedures.
In 2009 he was appointed as Head of Section for Anti-infectives and vaccines in the Safety & Efficacy Sector, Human Medicines Development and Evaluation Unit.
Margherita Coccia is a Director for Adjuvant Science and Technology at GSK. She received a M.Sc. in Biotechnology from the University San Raffaele in Milan and a PhD in Immunology from the Dunn School of Pathology at Oxford University. Margherita joined GSK in 2013 and has been involved in vaccine discovery ever since. Her main interests lie in the science of adjuvants and adjuvanted vaccines, with a focus on leveraging the interface between data science and immunology to design new immunostimulants and support highly potent vaccines.
Martin Friede, PhD, is an internationally recognized expert in vaccine research and development with more than three decades of leadership experience spanning global health, industry, and academia. His career has focused on advancing vaccine technologies, strengthening biomanufacturing capacity in low- and middle-income countries, and guiding high-impact global health initiatives.
Dr. Friede served at the World Health Organization (WHO) from 2003 to 2025, most recently as Head of the Vaccine Research Unit, where he led global programmes to define global vaccine R&D priorities, develop strategic innovation roadmaps, and expand access to cutting-edge vaccine technologies. He established and oversaw the WHO mRNA Technology Transfer Programme, enabling the development of sustainable mRNA vaccine and therapeutics manufacturing capacity across multiple regions. Since September 2025, he has been a Senior Advisor to the Medicines Patent Pool (MPP).
Melanie Saville, MBBS, is PATH’s Chief Scientific Officer. She leads PATH’s product development division, which includes a global team dedicated to the development, introduction, and scale of vaccines, medical devices, and diagnostics.
Dr. Saville is a distinguished physician specializing in virology with more than two decades of experience developing and licensing vaccines for global use. Her contributions over the past 20 years have included the development of vaccines for seasonal and pandemic influenza, as well as pediatric combinations and vaccines against rabies, Japanese encephalitis, dengue, Ebola, and SARS-CoV-2.
Before joining PATH, Dr. Saville worked with the Coalition for Epidemic Preparedness Innovations (CEPI), where she served as the Executive Director of Vaccine Research and Development, leading technical teams supporting vaccine development. She also served as the R&D and manufacturing workstream leader for COVAX, part of a global collaboration to speed development, production, and equitable access to COVID-19 tests, treatments, and vaccines.
Dr. Saville holds a medical degree, a master’s degree in medical virology, and a Bachelor of Science in molecular biology from University College, London.
Michel De Wilde holds a PhD in Biochemistry and has a long and successful career in Vaccine Research and Development. He currently consults for the vaccine community and is member of several Scientific Advisory Boards
From 2001 till June 2013, Michel De Wilde was Senior Vice President, Research & Development, at sanofi pasteur where he drove the development and licensure of a number of products.
From 1978 till 2000, De Wilde was at SmithKline Beecham Biologicals (now GSK Vaccines) where he held positions of increasing responsibility. He played a key role in the development of several new vaccines, most notably the recombinant Hepatitis B vaccine, as well as GSK’s Malaria vaccine.
Dr. Nakorn Premsri is a Director of NVI, Thailand, appointed in February 2019. He has the extensive experiences in health promotion, disease prevention and control as well as public health program management. He completed his medical training from Faculty of Medicine, Chulalongkorn University, Thailand, in 1993. He worked on public health management at Department of Disease Control, Ministry of Public Health for 16 years
before moving to NVI. Importantly, he also has been working in vaccine development field since 2003.
As Director of NVI, He develops and manages national policies and strategies for vaccine security. He manages national funding to support vaccine research and development, production, and vaccination towards national vaccine security and self-reliance. He also facilitates collaboration with national and international vaccine partners, establishes
a vaccine information center for policy decision making and builds capacity among vaccine experts and human resources. Dr. Nakorn proposed the ASEAN Vaccine Security and Self-Reliance (AVSSR) initiative, to be endorsed at the ASEAN Summit in November 2019 with support from the ASEAN Health Minister Meeting. As AVSSR Focal Point, Dr. Nakorn is responsible for coordinating the implementation of the AVSSR Strategic and Action Plan 2021-2025 to ensure regional vaccine security.
Nigel obtained his BSc in Microbiology and Genetics from University College London (UCL) in 1990 and an MSc in Applied Molecular Biology of Infectious Diseases (1992), PhD in Molecular Parasitology (1999) and DLSHTM (2000) from the London School of Hygiene & Tropical Medicine (LSHTM). After his PhD, he returned to UCL as a post-doctoral scientist in the Division of Infection and Immunity. In 2009 Nigel was elected as a member of the highly prestigious Medical Research Club and set up his own research group at the University of Kent. He is currently Chair and Professor in Molecular Virology, Director of the Viral Pseudotype Unit (VPU) and Director of Research and Innovation. Nigel is a Fellow of the Royal Society of Biology (FRSB), Senior Associate Member of the Royal Society of Medicine (RSM), Member of the International Society for Influenza and other Respiratory Virus Diseases (ISIRV), the Microbiology Society and the European Society for Virology (ESV). Nigel acts as external consultant for VisMederi (Italy) and RQbio (UK). He has published over 200 articles with an h-index of 53, >14k citations.
Dr Norbert Pardi holds a Ph.D. in biochemistry and genetics. He has been working at the University of Pennsylvania since 2011 and currently holds an Assistant Professor position at the Department of Microbiology of the Perelman School of Medicine. His research interest is the development of mRNA-based therapeutics with particular focus on new generation infectious disease vaccines. He explored the development of a novel vaccine platform using nucleoside-modified mRNA in lipid nanoparticles (LNPs) and used it to generate highly effective vaccines targeting various pathogens (influenza virus, coronaviruses, malaria and others). Dr. Pardi is a pioneer of the nucleoside-modified mRNA vaccine technology and published milestone papers in the field.
Noriko Tomita, PhD Project Manager for Research Collaboration and Development. Education; 1992–1996; Faculty of Agriculture, Tohoku University, Japan (Awarded the degree of B.S.). 1996–1998; Graduate School of Agricultural Science, Tohoku University, Japan (Awarded the degree of M.S.). 1998–2001; Graduate School of Agricultural Science, Tohoku University, Japan (2001; Awarded the degree of Ph.D. from Tohoku University). JSPS Research Fellow (DC1) during this period. Brief chronology of employment; 2001–2004; JSPS Postdoctoral Research Fellow (PD), Graduate School of Agricultural Science, Tohoku University (Sendai, Japan). 2004–2006; Research Fellow, Graduate School of Agricultural Science, Tohoku University (Sendai, Japan). 2006–2009; Technical Research Assistant, Biomedical Engineering Research Organization / Graduate School of Biomedical Engineering, Tohoku University (Sendai, Japan). 2009–2013; Global COE Fellow (2009–2010) and JSPS Research Fellow (RPD) (2011–2013), Institute of Fluid Science, Tohoku University (Sendai, Japan). 2010, 2011, and 2012–2013; Senior Visiting Research Fellow, Department of Physics, Syracuse University (Syracuse, USA). 2014–2019; Medical Device Reviewer and Reliability Assurance Inspector, Pharmaceuticals and Medical Devices Agency (PMDA) (Tokyo, Japan). 2020–2023; Senior Researcher, subsequently Chief Researcher, Center for Clinical Sciences, National Center for Global Health and Medicine (Tokyo, Japan). 2023–Present; Specially Appointed Associate Professor and Project Manager for Research Collaboration and Development, Center for Advanced Modalities and Drug Delivery System (CAMaD), The University of Osaka (Osaka, Japan).
Peter Dull is the deputy director for Integrated Clinical Vaccine Development within the Global Health Division. In this role, he provides technical and strategic guidance on clinical development to the foundation’s program strategy teams, including Pneumonia and Enteric and Diarrheal Diseases, and external partners. In addition, he leads the foundation’s vaccine development activities for HPV vaccines, including efforts with reduced dose schedules.
Peter joined the foundation in 2014 after 10 years at Novartis Vaccines and Diagnostics where he was the clinical franchise head for Meningitis and Sepsis Vaccines. During that time, he led the clinical development and global licensure for a quadrivalent meningococcal glycoconjugate vaccine (Menveo; MenACWY-CRM) as well as a protein-based serogroup B meningococcal vaccine (Bexsero; 4CMenB). His work also included early clinical development of Group B strep glycoconjugate and Staph aureus vaccines. Prior to joining Novartis, he was an epidemic intelligence service officer in the Meningitis and Special Pathogens Branch at the U.S. Centers for Disease Control and completed subspecialty training in infectious diseases at Emory University.
He received his medical degree at University of Wisconsin-Madison and Internal Medicine training at Oregon Health Sciences University.
Zhang Qiong is a Principal Investigator at the Guangzhou National Laboratory and a member of the GZNL-CDE "Research-Review " Innovative Vaccine Project Team. She serves as a reviewer expert at the Center for Drug Evaluation (CDE), National Medical Products Administration (NMPA), where she has been deeply involved in developing three technical guidelines related to mRNA vaccines. Dr. Zhang is recognized as a Youth Top Talent under Guangdong Province's ZJ Talent Program and completed her postdoctoral research at the University of California, San Diego (UCSD). Her research focuses on molecular virology and developing intervention strategies for viral infectious diseases. She has published 23 SCI papers, which have garnered over 1700 citations, with an H-index of 18. Dr. Zhang has led two overseas talent programs and one National Natural Science Foundation project, and has been a core contributor to the "Guangzhou National Laboratory Major Scientific and Technological Special Project."
Rajinder as CEO-DCVMN International is responsible for leadership, governance, strategic vision and overall operational excellence of DCVMN. Rajinder is appointed as member GAVI’s Vaccine Investment Strategy (VIS) Steering Committee 2024, a permanent member of CEPI’s Joint Coordination Group (JCG), 2023-24, member PAVMs Talent Development WS and Regional Vaccine Manufacturing Collaborative (RVMC). To meet an un-precedented challenge posed by COVID-19, Rajinder has been actively involved in all global strategic initiatives along with COVAX partners-WHO, GAVI, CEPI, UNICEF and several other international organizations including industry associations to ensure equitable and timely access to vaccines. He has been member of several advisory expert groups including COVAX Manufacturing & Supply Chain Task Force Leadership Team, G-20 Health Working Group and Market Design and Demand Intelligence pillar of PAVM. Rajinder has over 25 years of top management experience in the industry including at the Board of Directors of the Indian subsidiary of Sanofi Pasteur and as CEO-Panacea Biotec. He has served as Member-GAVI-PPC as well as Vice-President, DCVMN Executive Committee.
Dr. Raman Rao joined as the Chief Executive Officer at Hilleman Laboratories in February 2020. Dr. Rao has more than two decades of experience in research and development, manufacturing and commercialisation of vaccines for infectious diseases in global pharma and biotech companies. Prior to joining Hilleman Laboratories, Dr. Rao served as the Vice President of Global Product Operations with Takeda, Singapore, where he enhanced the global product portfolio while successfully leading an international team across Japan, Singapore and the United States. The teams worked in the areas of dengue, norovirus, zika, polio and other vaccines.
Dr. Rao started his career in 2002 with Shantha Biotechnics Limited, part of Sanofi Aventis Group in India, in Clinical Research and Scientific Affairs. He holds a MD in Medical Microbiology from the Postgraduate Institute of Medical Education and Research.
He plans to carry forward Dr. Maurice Hilleman’s legacy for providing effective solutions for global health, especially those impacting low- and middle-income countries.
Rino Rappuoli is Scientific Director of the Biotecnopolo di Siena Foundation, Italy. He is also Honorary Professor of Vaccinology at Imperial College, London, and Senior Professor of Molecular Biology at the University of Siena. Prior positions held: Head R&D and Chief Scientist at GSK Vaccines, head of Vaccine R&D at Novartis, CSO at Chiron Corporation, head R&D at Sclavo.
He earned his PhD in Biological Sciences at the University of Siena, Italy, and was visiting scientist at Rockefeller University and Harvard Medical School.
He is elected member of US National Academy of Sciences (NAS), American Academy of Arts & Sciences (AAAS), American Institute for Medical and Biological Engineering (AIMBE), European Molecular Biology Organization (EMBO), Royal Society of London, Accademia Nazionale dei Lincei. Awards received: Gold Medal by the Italian President, Albert B Sabin Gold Medal, Canada Gairdner International Award, European Inventor Award for Lifetime Achievement, Paul Ehrlich and Ludwig Darmstaedter Prize, Robert Koch Award. He is President of the International Union of Microbiological Societies. He was voted the world's third-most influential person in the field of vaccines at the Terrapinn World Vaccine Congress in 2013. Currently, he is ranked second most important person worldwide in the specialty of vaccines by ScholarGPS. He has published 826 works in peer-reviewed journals and an H-index of 165.
He introduced novel scientific concepts: genetic detoxification; cellular microbiology; reverse vaccinology; pangenome. Developed licensed vaccines: acellular pertussis containing a non-toxic mutant of pertussis toxin; first conjugate vaccine against meningococcus C; conjugate vaccines against meningococcus ACYW, MF59-adjuvanted seasonal and pandemic influenza. MF59 was the first vaccine adjuvant approved for human use after the aluminum salts; meningococcus B by reverse vaccinology; cell culture-based influenza vaccine, respiratory syncytial virus, CRM 197 as carrier of most conjugate vaccines.
Founder of the GSK Vaccines Institute for Global Health (GVGH) Professor Rappuoli is among the world scientific leaders dedicated to the sustainability of global health.
Rita Carsetti trained in Medicine and Obstetrics and Gynecology at La Sapienza University of Rome (Italy) before discovering her passion for science during her postdoctoral training in the United States, at the M.D. Anderson Hospital in Houston (Texas). She followed this with a second postdoc at the Max-Plank Institute for Immunobiology in Freiburg (Germany), in the department of Georges Koehler, who had received the Nobel Prize for the discovery of monoclonal antibodies. At the Max-Planck she also became responsible for the flow cytometry core facility and later worked in the departments of Michael Reth and Thomas Boehm. After 13 years in Germany, she returned to Italy (Bambino Gesù Children’s Hospital, Rome) with a strong background in basic immunology of murine B cells. At this point she turned her attention to human B cells for a more patient-orientated research approach. The close contact with clinicians and her role as head of the Diagnostic Immunology Unit gave her the possibility to learn how human B cells change with age, immunodeficiency, infection, transplantation, and vaccination. The COVID-19 pandemic and the global vaccination campaign gave her the possibility to learn more about the development, function, and persistence of human memory B cells after vaccination in healthy subjects and patients with primary or secondary immunodeficiencies. Throughout her career, Rita Carsetti has made a number of discoveries regarding the development of human and murine B cell populations and the effect changes in such populations have on infection and immunodeficiencies in humans. Her recent work on SARS-CoV-2 and RNA vaccination has been vital in demonstrating how human memory B cells aid immune protection and how mucosal immunity is induced in neonates born to SARS-CoV-2 infected mothers. Altogether, Rita Carsetti’s work is extremely relevant to both basic and clinical immunologists.
Dr Robbert van der Most obtained his cum laude PhD in 1994 at Leiden University (Netherlands) on the topic of coronavirus molecular biology. He then conducted postdoctoral work on the immunology of chronic viral infection with Dr Rafi Ahmed(UCLA, Eiory University, USA) and flavivirus molecular biology with Dr Jim Strauss (Caltech, USA). Upon return to the Netherlands he worked on RSV vaccine immunology, focusing on the mechanisms of vaccine-enhanced disease. In 2004, he joined Dr Bruce Robinson's team at the University of Western Australia to study immune oncology and the immune-modifying effects of chemotherapy. In 2008, he joined GSK Vaccines in Belgium, in roles of increasing responsiblility, leadingTranslational Science, After a brief period at CEPl, he joined BioNTech as Vice-President Translational Science in 2022, leading a team of experts in the infectious disease portfolio, in 2024 he started his own consultancy business, aiming to provide scjentific and development advice to biotech and pharma companies, as well as not-for-profit organizations.
Dr. SeyedReza Banihashemi is the Head of Immunology Department and an Assistant Professor at Razi Vaccine and Serum Research Institute in Karaj, Iran. He holds a Ph.D. in Clinical Immunology from Tarbiat Modares University, Tehran. With over 20 years of experience in vaccine research and development, Dr. Banihashemi designed and developed Razi Cov-Pars, Iran's domestically produced COVID-19 vaccine. Under his leadership, Razi Institute successfully conducted Phase 1, 2 and 3 clinical trials of Razi Cov-Pars.this vaccine is first intranasal covid 19 vaccine in the world.
His research focuses on mucosal Immunity , intranasal vaccine , adjuvants, drug delivery systems, immune regulation and the development of bacterial and viral vaccines. He has published over 50 papers and authored book chapters in his field. His work on nanobody technology and immunoliposomes has applications for targeted drug delivery.
In addition to conducting research, Dr. Banihashemi teaches courses in infection and immunity. He has received several awards for his scientific contributions, including for exemplary research from Razi Institute.
When not engaged in his own work, Dr. Banihashemi reviews papers for international journals.
Dr. Tonya Villafana is Vice President, Franchise, Medical & Scientific Affairs, Vaccine & Immune Therapies at AstraZeneca. She has dedicated her career to protecting millions of people around the world from the most challenging infectious diseases.
Over her career, Dr. Villafana has developed vaccines and monoclonal antibodies targeting areas of distinct unmet medical need, including COVID-19, influenza, malaria and RSV among others. Most notably, Dr Villafana led the development of Beyfortus/nirsevimab, a novel long-acting RSV monoclonal antibody which was the first to offer protection against RSV disease to all infants entering their first RSV season. With over 45 approvals across the globe, over 6 million infants have received nirsevimab and effectiveness data demonstrates significant public health impact.
Dr. Villafana led the accelerated late-stage development of AstraZeneca’s COVID-19 vaccine, Vaxzevria, working with multiple stakeholders including the University of Oxford and COVAX to enable broad vaccine access. This once-in-a-generation effort led to more than 3.1 billion doses being delivered to 180 markets, saving an estimated 6 million lives. The Oxford-AstraZeneca team was awarded the Copley Medal for this achievement. Her team was also responsible for the development of AstraZeneca’s COVID-19 mAbs, Evusheld and Sipavibart.
Dr Villafana has held roles previously at the World Bank, at the PATH Malaria Vaccine Initiative and in academia at Harvard School of Public Health.
She has served on multiple scientific committees and advisory boards. In 2021, she was appointed as a Fellow of the International Society of Vaccines and in 2023, she was named as one of Endpoints News Top 20 Women in Biopharma R&D.
Dr Villafana received a PhD in immunology from Weill Cornell University Graduate School of Medical Sciences and an MPH from Harvard School of Public Health. She has over 60 publications in leading scientific journals including the NEJM, Lancet and Nature Medicine.
Prof Xu qualified in Medicine from Capital Medical University (Beijing) and obtained a PhD in Clinical Immunology from Flinders Medical Centre (Australia) and became the fellow of the Royal College of Pathologists of Australasia (FRCPA) in 1999. He then joined the group of Prof Sir Andrew J. McMichael as a NHMRC research fellow at Weatherall Institute of Molecular Medicine, University of Oxford.
In the past, Xiao-Ning served as Medical Research Council (MRC) Senior Clinical Scientist, project leader, and programme leader at MRC Human Immunology Unit (1995-2010), Oxford University, where he led research projects involving immune correlates of protection against emerging infectious diseases including HIV, SARS, and avian influenza. In 2010, he joined Novartis as the Head of Novartis Vaccines Research China, Novartis Vaccines & Diagnostics based in Shanghai, and in 2013, he became the Chair professor in Human Immunology at the Imperial College London based at South Kensington Campus.
Dr. Xuefeng Yu, Chairman and Chief Executive Officer of CanSino Biologics(CanSinoBIO), is one of the Co-founders of CanSino Biologics.
With more than 30 years of experience in the biopharmaceutical industry and rich experience in industrial development and business management, Dr. Yu returned to China in 2009 and led a team to establish CanSinoBIO, which focuses on the research, development, production and marketing of high-quality human vaccines. Over the past ten years, Dr. Yu has led his team in setting up five major technology platforms and formed a highly competitive product pipeline, including a number of innovative vaccine products for the prevention of more than 10 indications, including meningitis, pneumonia, pertussis, diphtheria, tetanus, COVID-19, Ebola virus disease, herpes zoster, and tuberculosis, etc., as well as innovative R&D collaborations with a number of research institutes around the world.
Dr. Yu holds a Ph.D. in Microbiology from McGill University, Canada, and received a B.S. degree in Biology and an M.S. degree in Microbiology from Nankai University. Prior to founding CanSinoBIO, Dr. Yu worked for Sanofi-Pasteur for many years, holding global management positions in its Product Development and Bacterial Vaccine Development Departments, and was one of the youngest executives at Sanofi Canada.
Yasuo Yoshioka， PhD
Group Leader，The Research Foundation for Microbial Diseases of Osaka University
Education;
1995-1999; Faculty of Pharmaceutical Sciences, Osaka University (Awarded the degree of B.S.).
1999-2001; Graduate School of Pharmaceutical Sciences, Osaka University (Awarded the degree of M.S.).
2001-2004; Graduate School of Pharmaceutical Sciences, Osaka University (2004; Awarded the degree of Ph.D. from Osaka University)
Brief chronology of employment;
2004-2006; Research Scientist, National Institute of Health Sciences (Tokyo, Japan)
2006-2012; Specially Appointed Associate Professor, The Center for Advanced Medical Engineering and Informatics, Osaka University (Osaka, Japan)
2012-2014; Associate Professor, Laboratory of Toxicology and Safety Science, Graduate School of Pharmaceutical Sciences, Osaka University (Osaka, Japan)
2015-2020; Specially Appointed Associate Professor, Vaccine Creation Project, BIKEN Innovative Vaccine Research Alliance Laboratories, Research Institute for Microbial Diseases, Osaka University (Osaka, Japan)
2020-2024; Specially Appointed Professor, Vaccine Creation Project, BIKEN Innovative Vaccine Research Alliance Laboratories, Research Institute for Microbial Diseases, Osaka University (Osaka, Japan)
2015-Present: Group leader, The Research Foundation for Microbial Diseases of Osaka University (Osaka, Japan)
Dr. Liu Yuanqing graduated from Shanghai Medical College of Fudan University and was a surgeon at Shanghai Zhongshan Hospital. He completed his PhD in Vrije Universiteit Brussel in Belgium and was one of the pioneers on myeloid-derived suppressors in tumors. He was previously a senior research lead at Sanofi Pasteur French headquarter, where he contributed to various vaccine projects, including cancer vaccines, vaccines against infectious diseases, pediatric vaccines, adjuvants, etc. Dr. Liu is an industry veteran with extensive experience in the development of innovative vaccines for international market. He was a member of the EU Innovative Medicine Initiative. Since 2021, he has been the Chief Scientific Officer of Immorna Biotechnology. He is based in Shanghai where Immorna has established a high-standard R&D site aiming to accelerate the development of mRNA vaccines and drugs in China.
Feng Zijian is a professor and doctoral supervisor at the School of Public Health and Emergency Management of Southern University of Science and Technology. He is a member of the Medical Emergency Expert Committee of the National Health Commission and the head of the Epidemiology Group, as well as the head of the Technical Working Group of the National Immunization Program Expert Advisory Committee. He is also the vice president of the Chinese Preventive Medicine Association and the deputy director of the Epidemiology Branch, the vice president of the Public Health Physician Branch of the Chinese Medical Doctor Association, a member of the Global Preparedness Monitoring Board (GPMB), the chief editor of the Chinese Journal of Preventive Medicine, and the deputy chief editor of China CDC Weekly and the Chinese Journal of Epidemiology.
He served as a researcher at the National Center for Disease Control and Prevention, deputy director of the National Immunization Program Center, director of the Office of Disease Control and Emergency Response, director of the National Center for Health Emergency Response, and deputy director of the National Center for Disease Control and Prevention. He participated in the investigation, assessment, and technical support for emergency management decision-making of a series of major infectious disease outbreaks, natural disasters, and industrial accidents, as well as the formulation of important infectious disease monitoring and control policies and national immunization program policies. He has published over 280 papers in academic journals such as the New England Journal of Medicine, Lancet, Journal of Infectious Disease, Emerging Infectious Disease, Health Affairs, Epidemiology, Chinese Journal of Epidemiology, and Chinese Journal of Preventive Medicine, and has edited (translated) many professional books. He has also supervised 50 master's and doctoral students.
He enjoys the special government allowance for experts of the State Council, and has been awarded the title of Outstanding Young and Middle-aged Expert with Distinguished Contributions by the former National Health and Family Planning Commission, as well as the Public Health and Preventive Medicine Development Contribution Award by the Chinese Preventive Medicine Association. He has won the Special Prize for National Scientific and Technological Progress and multiple science and technology awards from the Chinese Medical Association and the Chinese Preventive Medicine Association. In September 2020, he was honored with the title of Advanced Individual in the National Campaign Against COVID-19 by the Central Committee of the Communist Party of China, the State Council and the Central Military Commission.
曹云龙，北京大学生物医学前沿创新中心（BIOPIC）研究员、助理教授，北大-清华生命科学联合中心研究员，北京昌平实验室领衔科学家，国家优秀青年科学基金获得者。2014年毕业于浙江大学竺可桢学院物理学专业，2019年获得哈佛大学化学博士学位。在新冠疫情期间，他围绕新冠病毒B细胞免疫应答、特异性抗体的结构与功能等开展了系统性研究，其中新冠中和抗体药物研制、新冠体液免疫响应特征和新冠突变免疫逃逸机制的创新性研究结果为抗击疫情做出了突出贡献。以第一作者、通讯作者在Nature、Cell、The Lancet Infectious Diseases、Cell Host & Microbe等期刊上发表多篇相关研究文章。相关研究成果获评2022年度“中国科学十大进展”、2022年度“中国生命科学十大进展”。其本人受邀作为WHO新冠疫苗成分技术咨询小组（TAG-CO-VAC）成员、国际流行病防范创新联盟（CEPI）科学顾问，获评2022年度北京市杰出青年中关村奖、《麻省理工科技评论》中国区“35岁以下科技创新35人”、2022年度Nature十大人物，获得国家优秀青年科学基金资助。
Dexiang Chen, Doctor of Immunology, Mississippi State University, has been engaged in the development of vaccines and vaccine adjuvants in Pfizer, Novartis and PATH scientific and technological organizations for more than 30 years, and has presided over a number of major international public health special projects funded by international organizations, foundations and national governments. Among the more than 20 infectious disease vaccine development projects presided over and participated in, many products have been listed globally. Dr. Chen Dexiang has published more than 60 vaccine-related academic papers in world-class academic journals such as Science and Nature Medicine.
Lianpan Dai, PhD, Principal Investigator at Institute of Microbiology, Chinese Academy of Sciences. He received his doctor's degree from Technical University of Munich (TUM), Germany. His research is mainly focused on the design and development of novel vaccines against major pathogens and the mechanism of protective immune response. Important research and translational achievements have been made in the research and development of vaccines against coronaviruses, Zika virus and other emerging infectious diseases, among which the recombinant protein subunit COVID-19 vaccine has been approved for use in many countries. The results are published as first/corresponding authors in the journals including Cell, The New England Journal of Medicine, Lancet, Nature Immunology, Nature Reviews Immunology, Cell Host & Microbe. He is supported by the National Science Fund for Excellent Young Scholars, and is the winner of VCANBIO Award for Biosciences and Medicine, excellent member of the Innovation Promotion Association of Chinese Academy of Sciences, the Young Scholar Award of Chinese Society of Immunology, and China Patent Silver Award Winner.
George Fu Gao has been a key leader in the public health field, making remarkable contributions to research and discovery through basic research, clinical evaluation and advocacy. He has made many remarkable contributions to the scientific field of control and prevention of emerging infectious diseases. He obtained his DPhil degree from Oxford University, UK and did his postdoc work in both Oxford University and Harvard University (with a brief stay in Calgary University). Gao worked in Beijing Agricultural University (1986-1991), Oxford University (2001-2006), Institute of Microbiology, Chinese Academy Sciences (2004-2008, Director-General). China CDC (Director-General, 2017-2022), National Science Foundation of China (Vice-President, 2018-2022). Gao is a member (academician) of Chinese Academy of Sciences (CAS), an international member of the U.S. National Academy of Sciences (NAS), a foreign member of the U.K. Royal Society (RS), a member of the German National Academy of Sciences Leopoldina, a fellow of African Academy of Sciences and a fellow of The World Academy of Sciences (TWAS).
顾江，陆军军医大学国家免疫生物制品工程技术研究中心副主任、教授，博士生导师，国家重点研发计划首席科学家，“国防优才基金”获得者，军队高层次青年英才，陆军科技英才，陆军军医大学科研名师，享受军队优秀专业技术人才津贴。国家重点领域严重感染致病菌疫苗研发创新团队核心骨干；重庆英才创新创业示范团队核心骨干。中国疫苗行业协会细菌感染与疫苗研究专委会常委、秘书长，重庆微生物学会理事。先后获重庆市技术发明一等奖、军队科技进步二等奖等奖励。主要从事结构疫苗学基础与临床研究，围绕超级耐药菌的免疫干预展开，研制了1.1类新药——基因工程铜绿假单胞菌疫苗实现成果转化，合同金额2.8亿元。
主任医师，暨南大 学讲席教授。暨南大学疫苗产业研究院／疾病预防控制研究院院长。曾任中国疾控中心副主任。现在兼任中国卫生有害生物防制协会会长、中华预防医学会副会长，世界卫生组织病毒性肝炎防控委员会委员、西太区免疫接种技术委员会委员、世界公共卫生联盟执委、中华预防医学会医疗机构公共卫生管理分会主任委员等职务。
主要从事疫苗接种，传染病控制，慢性病危险因素监测和疾病负担研究。承担传染病防治科技重大专项“乙型肝炎病毒免疫预防新策略的研究”研究。作为第一作者和责任作者，分别在新英格兰杂志、柳叶刀和疫苗杂志发表多篇学术论文。
获得了国务院特贴和卫生部有突出贡献中青年专家称号。2013年获得“吴阶平杨森医学药学奖”。2014年，“我国首次对甲型H1N1流感大流行有效防控及集成创新性研究”获得国家科技进步一等奖。2023年选为“广东省重大人才工程项目杰出人才”。2024年获广东省疾控中心高层次引进人才。
Shaowei Li Ph.D. Professor of Biochemistry and Structural Vaccinology, Xiamen University Shaowei Li is a tenured Professor of Biochemistry and Structural Vaccinology in the School of Life Sciences with a joint appointment in the School of Public Health, Xiamen University, China. He is the vaccine group leader in the National Institute of Diagnostics and Vaccine Development in infectious diseases (NIDVD), one of the academic leaders in the State Key Laboratory of Molecular Vaccinology and Diagnostics, deputy director in Fujian provincial Xiang An biomedicine laboratory. Dr. Li has inter-disciplinary research interests focusing on structural vaccinology, resulting in more than 120 peer-reviewed papers. He also has translational experience in vaccine development against infectious diseases—such as Hepatitis E vaccine and HPV vaccine, especially in aspects of immunogen design, process development and antigen characterization. Dr. Li has won two of China’s National Science and Technology Awards and been listed in the Top 20 translational researchers of 2016, ranked by Nature Biotechnology. He has served on the Product Development for Vaccines Advisory Committee (PDVAC), World Health Organization (WHO) since 2022.
Prof. Yuelong Shu
Director, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College. He is a member of the Chinese Academy of Medical Sciences and a Fellow of the American Academy of Microbiology. He was selected as the first batch of ‘National Science and Technology Innovation Leader’and‘2014 Top Ten Scientific and Technological Innovators’, and is the winner of National Science Fund for Distinguished Young Scholars and the China Youth Science and Technology Award. He has been honored with the National Science and Technology Progress Grand Prize, First Prize, Second Prize, the National Medical and Health System Advanced Individual, the National Innovation Award, the Public Health and Preventive Medicine Development Contribution Award, etc. He is currently the Chairman of the Branch of Medical Virology of the Chinese Medical Association and the Chairman of the Asia-Pacific Alliance for the Control of Influenza (APACI). He was the founding dean of the School of Public Health of Sun Yat-sen University (Shenzhen), the editor-in-chief of the Chinese Journal of Virology, the deputy director of the Institute of Viral Diseases of the Chinese Center for Disease Control and Prevention (CDC), the director of the National Influenza Center, and the director of the WHO Collaborating Center for Reference and Research on Influenza.
Shu has long focused on influenza prevention and control research, and has made outstanding achievements in the discovery of new viruses, the development of detection reagents, and the pathogenesis of infection. Through the systematic establishment of new influenza detection and surveillance technology, it was found for the first time in the world that a variety of new avian influenza viruses such as H7N9, H5N6 and H10N8 can lead to human infection and death; The first successful development of pandemic H1N1 2019 and H7N9 avian influenza detection reagent; The origin, evolution and infection mechanism of H7N9 and other avian influenza viruses were clarified, which provided key scientific and technological support for the successful prevention and control of the epidemic in China. He has published nearly 200 papers in Science, Nature, NEJM, Lancet and other academic journals as a corresponding author. The research results were selected as one of the ‘China’s 100 most influential international academic papers in 2013’and ‘2013 Top Ten Scientific Advances in China’.
Dr. Bin Wang is the Co-founder, Chairman of Advaccine Biotechnology Co LTD. He is also holding a distinguished professor position at the Fudan University School of Basic Medical Sciences and serves as the chairman for the Nucleic Acid Vaccines branch of the Chinese Vaccine Society. His research area is focused on the effects of therapeutic vaccination to activate T cells and the mechanism of immune regulations. He has developed novel adjuvants and recombinant vaccines, novel DNA vaccine delivery, and led to several developed vaccines being tested in human clinical trials. He received his Ph.D. from the Cincinnati Children's Hospital at the University of Cincinnati School of Medicine in 1990. He completed his postdoc training in virology and immunology at the Wistar Institute in 1992 in Philadelphia. He became an instructor and assistant professor at the University of Pennsylvania Medical School from 1993 to 1998. He was a professor and served as the Chairman of the Department of Microbiology and Immunology for six years at the College of Biological Sciences, China Agricultural University before he joined Fudan University. He was one of the very early DNA vaccine technology inventors in the 90’s and performed the first-in-human DNA vaccine trials in 1994-1996. He has been involved in several clinical trials of therapeutic vaccines against chronic HBV infections in recent years and invented a novel prophylactic RSV vaccine currently under clinical phase II testing. He has published over 160 peer-review articles and awarded 35 US and 30 Chinese patents. He serves as an editorial board member for several international journals and executive member in several professional societies.
英博博士于2019年创立艾博生物，为公司创始人、董事长兼首席执行官。创立至今，艾博生物已建立起具有自主知识产权的mRNA和纳米递送技术平台，推动mRNA科学技术应用赋能创新医疗产品开发。
英博博士拥有国际化的行业视野和丰富的核酸药物开发领域工业界经验，精通RNA药物设计和纳米制剂产业化。创立艾博生物前，他曾在多家全球领先的核酸药物研发机构任核心研发团队负责人，领导开展包括小核酸（siRNA）、mRNA及基因编辑产品的开发及大规模工业化生产等工作。
英博博士本科、硕士毕业于复旦大学，并在美国东北大学获得药剂学博士学位。英博博士曾在Cell、Lancet等多个重要国际期刊发表论文，他也是多项海外授权专利发明人。2018-2019年期间，英博博士任波士顿美中生物医药协会（Chinese-American BioMedical Association）会长，服务生物医药科研和工业技术的深度融合。
